Business
Viatris Announces Appointment of Scott A. Smith as CEO Effective April 1, 2023
Smith, a seasoned senior healthcare executive, will lead the company's previously announced Phase 2 strategy and execution Board of Directors thanks Michael
About this update from Viatris Inc.
[{"type":"text","content":"Smith, a seasoned senior healthcare executive, will lead the company's previously announced Phase 2 strategy and execution\nBoard of Directors thanks Michael Goettler, who will support a smooth transition prior to his departure \nPITTSBURGH, Feb. 27, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that as it prepares to enter Phase 2 of its previously announced strategic plan in 2024, Scott A. Smith has been appointed by its Board of Directors to lead the execution of that plan as Viatris' new Chief Executive Officer, effective April 1, 2023. In the interim, current CEO Michael Goettler will be working closely with Smith to support a smooth transition and will then depart as CEO and as a member of the board.\n\nSmith has been a member of the Viatris Board since December 2022 and is a deeply knowledgeable senior global biotechnology and pharmaceutical executive with more than 35 years of experience. As a former President and Chief Operating Officer at Celgene Corporation, he rose up the ranks, including holding the roles of SVP and Global Head of Immunology, as well as President of Inflammation and Immunology.\nMost recently, he served as President of BioAtla, Inc., a publicly traded global biotechnology company focused on the development of Conditionally Active Biologics™ (BAC) antibody therapeutics.\nThe Viatris Board believes that Smith is a seasoned builder who possesses vast global commercial and pharmaceutical expertise and a proven ability to build, grow and manage large complex organizations. He also has substantial experience in developing and executing regulatory, clinical, and business development strategies. One of his many achievements during his 10-year career at Celgene was to build and oversee the clinical development, registration, launch and global commercial success of the blockbuster drug Otezla®.\nRobert J. Coury, Executive Chairman of Viatris said, \"As we now prepare to enter into Phase 2 of our evolution for 2024 and beyond, we believe Scott Smith is the absolute right leader to guide Viatris into a period of renewed growth and leadership in our sector. The Board sees his strong commercial and strategic expertise being complemented by his experience in organically building product franchises, business development and partnering activities. I have personally be...